Related Experiment Video

Updated: Jan 25, 2026

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.1K

Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases

Dagmar Kubitza1, Sylvia Haas

  • 1Bayer HealthCare AG, Clinical Pharmacology, Aprather Weg 18a, Wuppertal, Germany. dagmar.kubitza@bayerhealthcare.com

Expert Opinion on Investigational Drugs
|July 25, 2006
PubMed

Insights

Novel anticoagulants targeting coagulation factor Xa are urgently needed. This review discusses direct and indirect factor Xa inhibitors, including rivaroxaban, and their clinical developments for treating thromboembolism.

Area of Science:

  • Pharmacology
  • Thrombosis
  • Drug Development

Background:

  • Urgent need for novel anticoagulants beyond unfractionated heparins, low molecular weight heparins, and vitamin K antagonists.
  • Coagulation factor Xa is a key target due to its central role in both intrinsic and extrinsic clotting pathways.

Purpose of the Study:

  • To review the pharmacological effects of factor Xa inhibitors.
  • To discuss the latest clinical developments in factor Xa inhibitor drug discovery.

Main Methods:

  • Review of existing literature on factor Xa inhibitors.
  • Analysis of indirect (e.g., fondaparinux) and direct (e.g., rivaroxaban) inhibition strategies.
  • Examination of clinical trial data for key factor Xa inhibitors.

Main Results:

  • Fondaparinux is approved for venous thromboembolism; idraparinux is in Phase III trials.
  • Rivaroxaban has completed Phase II studies for orthopedic surgery and initiated Phase III trials.
  • Several direct factor Xa inhibitors (DX-9065a, otamixaban, LY517717, YM150) are under investigation.

Conclusions:

  • Factor Xa inhibitors represent a promising class of novel anticoagulants.
  • Both indirect and direct inhibition strategies are being actively pursued in clinical development.
  • Ongoing research and clinical trials are crucial for advancing anticoagulant therapies.

More Related Videos

Platelet-Rich Plasma Lysate for Treatment of Eye Surface Diseases05:57

Platelet-Rich Plasma Lysate for Treatment of Eye Surface Diseases

Published on: August 2, 2022

5.0K
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.6K

Related Concept Videos

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
616
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
10.9K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.0K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
850
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
586
Pathophysiology of Peptic Ulcer Disease: Injurious Factors01:22

Pathophysiology of Peptic Ulcer Disease: Injurious Factors

Peptic ulcers are sores on the stomach's inner lining and the upper small intestine, which are the result of disruptions in the mucosal layer that houses parietal cells which produce gastric acid, and chief cells which secrete pepsinogen.
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
1.2K